"Cyclophosphamide" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.
| Descriptor ID |
D003520
|
| MeSH Number(s) |
D02.455.526.728.650.730.243 D02.705.672.500.243
|
| Concept/Terms |
Cyclophosphamide- Cyclophosphamide
- Cytophosphane
- Cyclophosphamide Monohydrate
- Monohydrate, Cyclophosphamide
- Cyclophosphane
|
Below are MeSH descriptors whose meaning is more general than "Cyclophosphamide".
Below are MeSH descriptors whose meaning is more specific than "Cyclophosphamide".
This graph shows the total number of publications written about "Cyclophosphamide" by people in this website by year, and whether "Cyclophosphamide" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 4 | 4 |
| 1998 | 1 | 3 | 4 |
| 1999 | 1 | 1 | 2 |
| 2000 | 0 | 6 | 6 |
| 2001 | 1 | 3 | 4 |
| 2002 | 2 | 7 | 9 |
| 2003 | 1 | 1 | 2 |
| 2004 | 2 | 5 | 7 |
| 2005 | 3 | 3 | 6 |
| 2006 | 1 | 4 | 5 |
| 2007 | 4 | 6 | 10 |
| 2008 | 4 | 6 | 10 |
| 2009 | 2 | 8 | 10 |
| 2010 | 7 | 6 | 13 |
| 2011 | 0 | 10 | 10 |
| 2012 | 5 | 3 | 8 |
| 2013 | 7 | 9 | 16 |
| 2014 | 4 | 7 | 11 |
| 2015 | 7 | 10 | 17 |
| 2016 | 9 | 4 | 13 |
| 2017 | 7 | 4 | 11 |
| 2018 | 2 | 11 | 13 |
| 2019 | 5 | 13 | 18 |
| 2020 | 3 | 17 | 20 |
| 2021 | 3 | 10 | 13 |
| 2022 | 1 | 17 | 18 |
| 2023 | 0 | 13 | 13 |
| 2024 | 2 | 9 | 11 |
| 2025 | 1 | 6 | 7 |
| 2026 | 0 | 4 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Cyclophosphamide" by people in Profiles.
-
Regulation of mitochondrial ROS by C15ORF48 in a basal cell subpopulation contributes to chemotherapy resistance in TNBC. Sci Adv. 2026 Apr 03; 12(14):eaec8684.
-
Efficacy and Tolerability of Topotecan/Cyclophosphamide/Dinutuximab in Relapsed and Refractory High-Risk Neuroblastoma: A Multi-Institutional Retrospective Study. Pediatr Blood Cancer. 2026 May; 73(5):e70195.
-
The role of amygdala calcitonin gene-related peptide receptors on the development of persistent bladder pain in mice. Pain. 2026 Jun 01; 167(6):1440-1452.
-
Anti-CSF-1R therapy with combined immuno-chemotherapy coordinate an adaptive immune response to eliminate macrophage enriched triple negative breast cancers. Nat Commun. 2026 Jan 03; 17(1):1193.
-
A composite endpoint for systemic sclerosis-associated interstitial lung disease: association with mortality in two clinical trial cohorts. Respir Res. 2025 Nov 28; 26(1):337.
-
Successful Treatment of Double-Positive Rapidly Progressive Glomerulonephritis: A Case Report. J Investig Med High Impact Case Rep. 2025 Jan-Dec; 13:23247096251365418.
-
Impact of quantitative radiological features of interstitial lung disease on immunomodulatory treatment response in three autoimmune interstitial lung disease cohorts. Thorax. 2025 07 15; 80(8):540-546.
-
Mosunetuzumab plus Pola-CHP compared with Pola-R-CHP in previously untreated DLBCL: final results from a phase 2 study. Blood Adv. 2025 May 27; 9(10):2461-2472.
-
Improved outcomes of acute lymphoblastic leukemia after allogeneic blood or marrow transplantation with highdose post-transplantation cyclophosphamide in the era of more effective pre-transplant therapy. Haematologica. 2025 Nov 01; 110(11):2635-2646.
-
Hematology-oncology provider perspectives regarding lymphoma treatment and cardioprotective strategies in patients with lymphoma at high risk for heart failure. Leuk Lymphoma. 2025 Aug; 66(8):1437-1446.